American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: May 2021 update on the use of intermediate-intensity anticoagulation in critically ill patients.

Autor:	Cuker A; Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Tseng EK; St. Michael's Hospital, Division of Hematology/Oncology, University of Toronto, Toronto, ON, Canada., Nieuwlaat R; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Angchaisuksiri P; Division of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand., Blair C; Union, NJ., Dane K; Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD., Davila J; Children's Hospital at Montefiore, Division of Pediatric Hematology, Oncology, and Cellular Therapies, Albert Einstein College of Medicine, Bronx, NY., DeSancho MT; Division of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY., Diuguid D; Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY., Griffin DO; Department of Medicine, Division of Infectious Diseases, College of Physicians and Surgeons, Columbia University, New York, NY.; Research and Development at United Health Group, Minnetonka, MN.; Prohealth NY, Lake Success, NY., Kahn SR; Department of Medicine, McGill University, Montreal, QC, Canada., Klok FA; Department of Internal Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands., Lee AI; Section of Hematology, School of Medicine, Yale University, New Haven, CT., Neumann I; Department of Internal Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile., Pai A; Division of Hematology and Oncology, Kaiser Permanente, Oakland/Richmond, CA., Righini M; Division of Angiology and Hemostasis, Faculty of Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland., Sanfilippo KM; Department of Medicine, Washington University School of Medicine St. Louis, St. Louis, MO., Siegal D; Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada., Skara M; Cottage Grove, MN., Terrell DR; Department of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK., Touri K; Toronto, ON, Canada., Akl EA; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon., Bou Akl I; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon., Bognanni A; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Boulos M; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada., Brignardello-Petersen R; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Charide R; Clinical Research Institute, American University of Beirut, Beirut, Lebanon., Chan M; Department of Medicine, McMaster University, Hamilton, ON, Canada., Dearness K; Library Services, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada., Darzi AJ; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Kolb P; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada., Colunga-Lozano LE; Department of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico., Mansour R; Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan., Morgano GP; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Morsi RZ; Department of Neurology, University of Chicago, Chicago, IL., Muti-Schünemann G; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Noori A; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.; The Michael G. DeGroote National Pain Center, McMaster University, Hamilton, ON, Canada., Philip BA; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Piggott T; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Qiu Y; Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada., Roldan Y; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Schünemann F; Medizinische Fakultät, Albert-Ludwigs-Universität Freiburg, Freiburg, Germany., Stevens A; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Solo K; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Wiercioch W; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada., Mustafa RA; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.; Department of Internal Medicine, Division of Nephrology, University of Kansas Medical Center, KS; and., Schünemann HJ; Michael G. DeGroote Cochrane Canada, McGRADE Centre, Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.; Institute for Evidence in Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Jazyk:	angličtina
Zdroj:	Blood advances [Blood Adv] 2021 Oct 26; Vol. 5 (20), pp. 3951-3959.
DOI:	10.1182/bloodadvances.2021005493
Abstrakt:	Background: COVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE). Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in making decisions about the use of anticoagulation for thromboprophylaxis in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE. Methods: ASH formed a multidisciplinary guideline panel that included 3 patient representatives and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process by performing systematic evidence reviews (up to 5 March 2021). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update on guidelines published in February 2021. Results: The panel agreed on 1 additional recommendation. The panel issued a conditional recommendation in favor of prophylactic-intensity over intermediate-intensity anticoagulation in patients with COVID-19-related critical illness who do not have confirmed or suspected VTE. Conclusions: This recommendation was based on low certainty in the evidence, which underscores the need for additional high-quality, randomized, controlled trials comparing different intensities of anticoagulation in critically ill patients. Other key research priorities include better evidence regarding predictors of thrombosis and bleeding risk in critically ill patients with COVID-19 and the impact of nonanticoagulant therapies (eg, antiviral agents, corticosteroids) on thrombotic risk. (© 2021 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu